REWIRED
Rewired , the robotics focused venture studio that invests in growth-stage technology ventures, is seeking to add new artificial intelligence and robotics investments to its portfolio. The portfolio currently encompasses innovations in machine learning, robotics, bionics, smart sensors, mapping and localization in the UK and USA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200330005016/en/
Backed by investors who believe that analysts are underestimating the prospects of AI , Rewired seeks to make investments of between $5m and $30m. Its status as a venture studio means that Rewired uniquely seeks to attain a substantial or majority position as an investor, and to then provide long term funding and expertise. The Rewired approach is to alleviate founders from the burden of constant fundraising so they can focus on growth, whilst avoiding the dilution that VC’s typically accept during multiple funding rounds.
Rewired is seeking to back ventures that require growth capital to scale existing proprietary solutions that have already been proven, with a clear pathway to profitable growth. Experienced founders and a management team with commercial credibility in the intended marketplace are also a prerequisite for a Rewired investment, as is acceptance that the venture studio seeks to take a significant equity stake and to play a very active role.
Rewired has also made two new appointments in its Swiss office to support future deal flow. Laurent Bischof has joined Rewired as a Board Director. In 2016 Laurent co-founded Bloom , the first AI platform dedicated to strategic analysis of social networks. He also has over 15 years of venture capital experience. Marc-Olivier Bertholet has joined Rewired as a special advisor with over 20 years of international biotech and MedTech experience.
Many of the ventures backed by Rewired have humanitarian applications . In October 2017 Rewired led the funding round for Mountain View-based Aromyx , a venture that has developed olfactory biosensors that enable machines to taste and smell. In 2019 Aromyx completed successful trials of its olfactory sensor technology with a global plastics and chemicals company. Less than 10% of the world’s plastics are currently being recycled, with odour quality being a major barrier to broad-scale recycling. The 2019 trials indicated that the Aromyx technology could help to raise global plastic recycling to between 60% and 80%.
In 2017 Rewired also backed Bristol-based Open Bionics , a robotics manufacturer that has developed the next generation of 3D-printed bionic limbs . The company’s ‘Hero Arm’ is the world’s first clinically approved 3D-printed bionic arm . Since its fundraising, Open Bionics has expanded and exported bionic arms to the USA, Europe Australia and New Zealand.
Based in London in the United Kingdom and Lausanne in Switzerland, Rewired is funded by investors including the Cascade Global multi-family office and the Kohli Ventures investment vehicle of Tej Kohli . Cascade Global is also an investor in the Rewired.GG sister fund, which in 2019 became Europe largest esports investor when it invested €34m in an esports team.
Laurent Bischof, newly appointed Board Director of Rewired said:
“The majority of Rewired investments are still in stealth mode. But we believe that artificial intelligence and robotics will change everything, from making businesses more efficient to improving healthcare and even extending human life . The ventures that Rewired seeks to back are building the technology platforms that will help to power the new economy.”
Amit Jain, CEO of Cascade Global said:
“There are unprecedented events in the world at the moment and it is vital that we continue to invest in building the future through funds like Rewired. The promise of the artificial intelligence economy offers unprecedented opportunities to improve every aspect of human life and Rewired seeks to back the ventures that will enable this future.”
Tej Kohli , investor in Rewired said:
“I believe that artificial intelligence will change the world for the better and will be the biggest thing to ever happen to humanity. I am fascinated by the technologies that will be needed in order to put artificial intelligence into everything. This is exactly where I have placed my investment focus and Rewired aligns with this investment outlook entirely.”
Josh Silverman, CEO of Aromyx said:
“Since Rewired recapitalised with $100m of new funding in 2019, the team has always been emphatic that they have the resources available for $20m+ of further funding that could be made available to us. This is commensurate with what I have come to learn is the Rewired philosophy - that founders are free to build their company without constant fund-raisings.”
About Rewired
Rewired is a robotics focused venture studio and investment fund. Established in 2017 in the United Kingdom and Switzerland, the Rewired thesis is that artificial intelligence can make every industry and everything that is around us perform better with minimal human input. Rewired is on a mission to master the constellation of technologies that will enable this AI economy. This involves looking past the capabilities of human perception and into new technologies that allow us to tap into and create entirely new modalities of data and advancements that will enable the optimal application of AI throughout everyday life.
Click here to watch a video about Rewired
Click here to visit the Rewired website
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005016/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom